-- Xiamen Amoytop Biotech (SHA:688278) signed an exclusive license agreement with Aligos Therapeutics for pevifoscorvir sodium, used for treating chronic hepatitis B.
Amoytop will pay an upfront $25 million, plus up to $85 million in regulatory and $335 million in sales milestones, plus royalties, according to a Friday filing with the Shanghai bourse.
The deal covers Mainland China, Hong Kong, Macao and Taiwan.
Shares of the drugmaker closed 1% lower Friday.